NO20060144L - Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav - Google Patents

Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav

Info

Publication number
NO20060144L
NO20060144L NO20060144A NO20060144A NO20060144L NO 20060144 L NO20060144 L NO 20060144L NO 20060144 A NO20060144 A NO 20060144A NO 20060144 A NO20060144 A NO 20060144A NO 20060144 L NO20060144 L NO 20060144L
Authority
NO
Norway
Prior art keywords
molecules
corin molecules
substituted
new modified
activation sequences
Prior art date
Application number
NO20060144A
Other languages
English (en)
Norwegian (no)
Inventor
Qingyu Mu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20060144L publication Critical patent/NO20060144L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20060144A 2003-06-11 2006-01-10 Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav NO20060144L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47768303P 2003-06-11 2003-06-11
PCT/US2004/018669 WO2004111225A1 (en) 2003-06-11 2004-06-09 Novel modified corin molecules having substitute activation sequences and uses thereof

Publications (1)

Publication Number Publication Date
NO20060144L true NO20060144L (no) 2006-01-10

Family

ID=33551745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060144A NO20060144L (no) 2003-06-11 2006-01-10 Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav

Country Status (15)

Country Link
US (1) US7176013B2 (pl)
EP (1) EP1636356A1 (pl)
JP (1) JP2007502132A (pl)
KR (1) KR20060022683A (pl)
CN (2) CN1836037A (pl)
AU (1) AU2004248192A1 (pl)
BR (1) BRPI0411353A (pl)
CA (1) CA2527361A1 (pl)
IL (1) IL172095A0 (pl)
MX (1) MXPA05013321A (pl)
NO (1) NO20060144L (pl)
PL (1) PL379196A1 (pl)
RU (1) RU2006100035A (pl)
WO (1) WO2004111225A1 (pl)
ZA (1) ZA200600224B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
TW200723151A (en) * 2005-12-07 2007-06-16 Era Digital Media Co Business website method
WO2009120760A1 (en) * 2008-03-28 2009-10-01 The Cleveland Clinic Foundation Corin for treating obesity and diabetes
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
US10314894B2 (en) * 2014-02-12 2019-06-11 The Cleveland Clinic Foundation Treatment of cardio-renal disease using PCSK6
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
CN105734070A (zh) * 2016-04-11 2016-07-06 苏州大学 Corin基因变异体及其用途
CN108066286B (zh) * 2016-11-10 2021-06-29 复旦大学 炔丙基半胱氨酸纳米粒长循环脂质体及其制备方法和用途
CN118530307B (zh) * 2024-06-14 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种阻断pts途径的多肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK275788A (da) * 1987-05-22 1989-02-03 Zymogenetics Inc Fibrinolytiske proteiner
US5869637A (en) 1996-07-22 1999-02-09 Incyte Pharmaceuticals, Inc. Human Kallikrein
WO1998024886A1 (en) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Mast cell protease that cleaves fibrinogen
WO1998036054A1 (en) 1997-02-13 1998-08-20 Amrad Operations Pty. Ltd. Novel molecules
AU9260598A (en) * 1997-08-22 1999-03-16 Boehringer Mannheim Gmbh Zymogenic protease precursors that can be autocatalytically activated and their use
EP0927764B1 (de) 1997-12-03 2004-05-26 Boehringer Mannheim Gmbh Chimäre Serinproteasen
JP4488140B2 (ja) * 1998-06-05 2010-06-23 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト セリンプロテアーゼであるコリン
US6420157B1 (en) * 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
JP2003521920A (ja) * 2000-02-03 2003-07-22 コルバス・インターナショナル・インコーポレイテッド 膜貫通セリンプロテアーゼをコードしている核酸分子、コードされたタンパク質、およびそれらに基づく方法
US6906176B2 (en) * 2000-06-19 2005-06-14 Dyax Corp. Enterokinase cleavage sequences
CN1231262C (zh) * 2000-09-04 2005-12-14 金晓骏 载脂蛋白b－100表位的模拟肽、其多联体和修饰肽,以及含有这些肽的疫苗组合物
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
US20040132156A1 (en) * 2002-10-04 2004-07-08 Schering Aktiengesellschaft Modified hepsin molecules having a substitute activation sequence and uses thereof

Also Published As

Publication number Publication date
BRPI0411353A (pt) 2006-07-11
MXPA05013321A (es) 2006-03-09
ZA200600224B (en) 2007-04-25
CA2527361A1 (en) 2004-12-23
IL172095A0 (en) 2009-02-11
PL379196A1 (pl) 2006-07-24
CN101109011A (zh) 2008-01-23
KR20060022683A (ko) 2006-03-10
WO2004111225A1 (en) 2004-12-23
US7176013B2 (en) 2007-02-13
JP2007502132A (ja) 2007-02-08
CN1836037A (zh) 2006-09-20
RU2006100035A (ru) 2006-08-27
EP1636356A1 (en) 2006-03-22
WO2004111225A8 (en) 2006-04-06
US20050003416A1 (en) 2005-01-06
AU2004248192A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
ATE534747T1 (de) 1l1rl-1 als marker für kardiovaskuläre erkrankungen
NO20070257L (no) Forbindelser, blandinger og metoder
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
NO20060144L (no) Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav
NO20092023L (no) Oligoribonuleotider og anvendelser derav
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
DE60137501D1 (de) Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
EA200801462A1 (ru) Связывающий днк-сайт активатора транскрипции, пригодный для экспрессии генов
NO20081014L (no) Sammensetninger
DE502007005857D1 (de) Isoliertes naturidentisches kollagen
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
DE602005008412D1 (de) Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen
EP1509251A4 (en) NUCLEIC ACIDS, POLYPEPTIDES, AND METHODS FOR MODULATING APOPTOSIS
WO2008140708A8 (en) Use of hdac inhibitors for treatment of cardiac rhythm disorders
NO20070780L (no) Celloverflateprotein.
EA200400438A1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии
ATE482976T1 (de) Defensinproteine
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
WO2007017154A3 (en) Human inhibitory anti-factor viii antibodies binding to the a2 domain
DE60325695D1 (de) Der eaat2-promotor und dessen verwendung
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
EA200701694A1 (ru) Ферментативное получение витамина с
NO20074562L (no) Fremgangsmater for behandling av Parkinsons sykdom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application